Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ESSA Pharma Inc EPIX

ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, Masofaniten (formerly EPI-7386), is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). Masofaniten is in development in combination with antiandrogen treatments in patients with prostate cancer who are earlier in their course of the disease. The Company is completing the clinical development of masofaniten as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).


NDAQ:EPIX - Post by User

Bullboard Posts
Post by RichyRich$on Oct 06, 2018 3:40pm
76 Views
Post# 28757944

Double Bottom for 2018 a Good Sign...

Double Bottom for 2018 a Good Sign...From a Technical Analysis standpoint... the double bottom this year of $3.00 in April and September is a good sign. A new low wasn't able to be made... which usually signals true bottom when at a multi year low. This time the rally should sustain in an uptrend but choppy. Especially with the new trial results not too far away.
Bullboard Posts